TrialNature communications2023

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.

Ainhoa Madariaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.